阅读说明：本技术 哈尔满在制备降脂药物中的应用 (Application of Harbin in preparation of lipid-lowering drugs ) 是由 徐峻 黎妍文 李冬利 刘文锋 张焜 于 2019-11-04 设计创作，主要内容包括：本发明涉及哈尔满在制备降脂药物中的应用,属于医药技术领域。本发明提供了哈尔满在制备降脂药物中的应用。本发明的哈尔满不仅能抑制前脂肪细胞分化,而且抑制脂肪合成,从而抑制脂肪积累。能用于制备降脂药物,为高血脂症、动脉粥样硬化、肥胖和非酒精性脂肪肝的治疗提供了新的药物选择。(The invention relates to an application of Harbin in preparing a lipid-lowering drug, belonging to the technical field of medicines. The invention provides an application of Harbin in preparing a lipid-lowering drug. The harpagne of the invention can inhibit not only the differentiation of preadipocytes, but also the synthesis of fat, thereby inhibiting the accumulation of fat. Can be used for preparing lipid-lowering medicines, and provides a new medicine selection for treating hyperlipidemia, atherosclerosis, obesity and non-alcoholic fatty liver disease.)

1. Application of Harbin in preparing medicine for reducing blood lipid is provided.

2. The use of claim 1, wherein the lipid-lowering agent is an agent that reduces fat accumulation.

3. The use of claim 1, wherein the lipid-lowering agent is an agent that inhibits adipocyte differentiation.

4. The use of claim 1, wherein the lipid-lowering drug is a drug that inhibits fat synthesis.

5. The use according to any one of claims 1 to 4, wherein the medicament is in the form of capsules, tablets, pills, granules, oral liquid or injections.

6. A lipid-lowering drug, wherein said drug comprises harpagne.

7. The lipid-lowering agent according to claim 6, further comprising a pharmaceutically acceptable carrier.

8. The lipid-lowering drug according to claim 6 or 7, wherein the drug is in the form of a capsule, tablet, pill, granule, oral liquid, or injection.

Technical Field

The invention relates to an application of Harbin in preparing a lipid-lowering drug, belonging to the technical field of medicines.

Background

Hyperlipidemia refers to high blood lipid level, which can directly cause diseases seriously harming human health, such as atherosclerosis, coronary heart disease, pancreatitis, etc. Hyperlipidemia can be classified into primary and secondary. Primary is associated with both congenital and genetic origin, either due to monogenic or polygenic deficiencies, abnormalities in receptors, enzymes or apolipoproteins involved in lipoprotein transport and metabolism, or due to environmental factors (diet, nutrition, drugs) and by unknown mechanisms. The secondary symptoms are caused by metabolic disorder diseases (diabetes, hypertension, myxedema, hypothyroidism, obesity, liver and kidney diseases, and adrenal cortex hyperfunction), or related to other factors such as age, sex, season, drinking, smoking, diet, physical activity, mental stress, emotional activity, etc.

The clinical manifestations of hyperlipidemia are mainly yellow tumors caused by intradermal deposition of lipids and arteriosclerosis caused by endothelial deposition of lipids in blood vessels. Although hyperlipidemia can cause xanthoma, its incidence is not very high; the development and progression of atherosclerosis is a slowly progressive process. Thus, in general, most patients do not have obvious symptoms and signs of abnormality. Elevated plasma lipoprotein levels are found in many cases when biochemical blood tests are performed for other reasons.

Dyslipidemia is often accompanied by a variety of cardiovascular risk factors. The reduction in blood lipid levels can reduce the incidence and mortality of cardiovascular disease as serum total cholesterol and low density lipoprotein cholesterol levels decrease. Therefore, the method has very important significance for controlling the blood fat level, improving the life quality of patients with hyperlipidemia and prolonging the life of the patients.

Harmane is mainly used for diseases such as tinea dermatosis, eczema, burn, venous ulcer and the like caused by fungi (trichophyton intertoe with MIC of 1.6-200.0 mu g/mL); harbin is a motility inhibitor at low doses and causes convulsions at high doses; harman can inhibit the transfer of active sodium, is Na⁺、K⁺-an atpase inhibitor; can be used as plant growth regulator and uterus stimulant. Clinically, harbin is used for treating diseases caused by low adrenaline or noradrenaline level, and can promote blood circulation to disperse blood stasis, and treat cough, overstrain and hematemesis, traumatic injury and irregular menstruation. The structural formula of harman is shown below:

however, at present, the effect of harbourne on fat synthesis after use is not clear. Therefore, the present project investigated the effect of harbourne on fat synthesis and differentiation by examining the effect of harbourne on proliferation of 3T3-L1 cells and RAW264.7 cells.

Disclosure of Invention

The present invention aims at overcoming the shortcomings of the prior art and providing the application of the Harbin in preparing the lipid-lowering medicine, wherein the Harbin can reduce the accumulation of fat, inhibit the differentiation of fat cells and inhibit the synthesis of fat.

In order to achieve the purpose, the invention adopts the technical scheme that: application of Harbin in preparing medicine for reducing blood lipid is provided.

As a preferred embodiment of the use according to the invention, the lipid lowering drug is a drug that reduces fat accumulation.

As a preferred embodiment of the use of the present invention, the lipid-lowering drug is a drug that inhibits differentiation of adipocytes.

As a preferred embodiment of the use of the present invention, the lipid-lowering drug is a drug that inhibits fat synthesis.

As a preferable embodiment of the application of the invention, the dosage form of the medicament is capsules, tablets, pills, granules, oral liquid preparations or injections.

The invention also provides a lipid-lowering drug, which contains harpagne.

As a preferred embodiment of the lipid-lowering drug of the present invention, the drug further comprises a pharmaceutically acceptable carrier.

As a preferred embodiment of the lipid-lowering drug of the present invention, the dosage form of the drug is capsule, tablet, pill, granule, oral liquid or injection.

Compared with the prior art, the invention has the beneficial effects that: the Harbin can reduce fat accumulation, inhibit fat cell differentiation and inhibit fat synthesis, and can be used for preparing lipid-lowering medicaments.

Drawings

FIG. 1 is a statistical graph of the effect of Harbin at various concentrations on proliferation of 3T3-L1 preadipocytes, RAW264.7 cells.

FIG. 2 is a statistical plot of the effect of different concentrations of harpagne on triglyceride levels in 3T3-L1 preadipocytes.

FIG. 3 is a graph of the staining of oil Red O by Harbin at various concentrations on the accumulation of fat in preadipocytes of 3T 3-L1.

FIG. 4 is a schematic representation of the effect of Harbin on different stages of differentiation of 3T3-L1 preadipocytes.

FIG. 5 is a statistical plot of the effect of Harbin on triglyceride content at various stages of differentiation of 3T3-L1 preadipocytes.

FIG. 6 is a graph of the staining of oil Red O by Harbin on the effects of fat accumulation during different stages of differentiation of 3T3-L1 preadipocytes.

Detailed Description

To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to the accompanying drawings and specific embodiments.

In the following examples, the technical means used are conventional means well known to those skilled in the art, and the reagents and materials of the present application are commercially available or otherwise publicly available, unless otherwise specified.